For the full story, click here.
Biogen has been hit hard after the failure of its drug Aduhelm.
The Massachusetts-based biotech company had high hopes in the first Alzheimer’s treatment in a generation earlier this year. But its approval and the lead-up to it are now under investigation.
Here & Now‘s Lisa Mullins talks with Damian Garde, a reporter with our partners at STAT, the health and medicine publication, about an in-depth report he wrote with Adam Feuerstein.
This article was originally published on WBUR.org.
Copyright 2021 NPR. To see more, visit https://www.npr.org.
